Abstract: Vanadium compounds useful to prevent and/or inhibit adhesion, migration, and invasion of proliferative cells into surrounding tissue.

Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

Abstract: Rare earth metal compounds are described which, due to their luminescence when irradiated with UV light, are suitable in particular for the marking of security-relevant items, such as documents or data carriers.

Abstract: The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.

Abstract: Disclosed herein is a composition comprising a non-dusting copper pyrithione dispersion comprising small solid particles of copper pyrithione dispersed in a liquid dispersant, said solid particles having a particle size within a range of from about 0.1 to about 10 microns and a median particle size of less than 3 microns. The dispersion is suitably employed as an antifouling additive for marine paints without risking worker exposure to copper pyrithione dust. Paints containing the small particle copper pyrithione exhibit improved antifouling performance in cold water, as compared to paint containing larger particle copper pyrithione.

Abstract: A method for the manufacture of a substance having an apoptosis-inducing ability characterized in including a step of subjecting at least one compound selected from the following (a), (b), (c) and (d) [excluding uronic acid and/or uronic acid derivatives; and compounds which contain uronic acid and/or uronic acid derivatives] to a heating treatment: (a) pentose; (b) pentose derivatives; (c) compounds containing pentose; (d) compounds containing pentose derivatives.

Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.

Abstract: This invention relates to a class of heterocycles and their metal complexes, and is particularly concerned with the use of these compounds in the preparation of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer. The invention also relates to the use of these heterocycles and the corresponding metal complexes in the preparation of medicaments and to compositions including the heterocycles or their metal complexes and to methods for preparing these compounds.

Abstract: A method for the protection of wood and other wood materials without affecting dimensional stability or surface integrity of the treated material is described. The method involves treating wood material with an iron salt and selected oxidants where the iron salt is preferably complexed with organic chelating ligands. Preferably, a microbicidal agent is also incorporated into the method to provide treated wood products that demonstrate excellent surface integrity, dimensional stability and retention of the infused microbicidal agents for extended periods of time without incurring the detrimental environmental effects of conventional chromium or copper-based inorganic salt preservation methods.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect. The zinc oxinate compositions are shown to be therapeutically effective against The therapeutic composition demonstrates selective toxicity with a therapeutic index of one-hundred percent on human lung cancer, breast cancer, melanoma, venereal warts, male veruoca warts, lesions produced by human papilloma virus, basal cell carcinoma, solar keratosis, and Kaposi's sarcoma. In veterinary applications where dogs, cats, and horses are the patients, the composition shows a one-hundred percent therapeutic index with selective toxicity against eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histiocytoma, and sebaceous adenoma.

Abstract: Novel organic arsonic compounds are described as tumor inhibiting, and cancer treating compounds. Methods and compositions for inhibiting tumor cells and treating cancer are also provided.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.

Abstract: The invention relates to new indazole derivatives, processes for their preparation, and their use in medicaments.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Abstract: A combination of interleukin 10 and methotrexate is used to suppress autoimmune diseases including arthritis and psoriasis. It has been discovered that administration of a combination of interleukin 10 and methotrexate causes suppression of T cell proliferation. Concurrent use of both agents avoids the toxicity associated with higher doses of methotrexate.

Abstract: The present invention discloses the use of bismuth subgallate in the inhibition of the production of nitric acid synthase. Also disclosed is the synergistic efficacy of bismuth subgallate in combination with borneol in the inhibition of the production of nitric acid synthase.

Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

Abstract: The present invention provides methods comprising one or more zinc ionophores for treating or reversing the effects of stress, including surgical stress in patients in need thereof.

Abstract: The invention provides hybrid pigments containing: (a) at least one benzimidazolone triphenodioxazine compound of the formula (I)  and (b) at least one pyrrolo-[3,4-c]-pyrrole compound, or (c) at least one thiazine-indigo compound, or (d) at least one quinacridone compound or (e) at least one copper phthalocyanine compound and a process for the preparation of such hybrid pigments and their use for the mass pigmentation of substrates, as colorants in electrophotographic toners and developers, in powders and powder coating materials, in ink-jet inks and in cosmetic compositions.

Abstract: A composition comprising a C3-5-alkyl-1,2-benzisothiazolin-3-one and the metal complex of a cyclic thiohydroxamic acid such as the 2:1 zinc salt of either 3-hydroxy-4-methylthiazol-2(3H)-thione or 1-hydroxypyridine-2-thione.

Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: A metal complex and its use for binding or cleaving a nucleic acid. The metal complex has the formula: M is Pt, Pd, Ni, Co, or Cu; X is aryl, heteroaryl, cyclyl, or heterocyclyl; Y is halogen, tosylate, mesylate, triflate, pyrophosphate, or carboxylate; each of A1 and A2, independently, is N or C; each of A3 and A4, independently, is N, S, or 0, wherein A1, A2, A3, and A4 taken together have one positive charge; and each of R1 and R2, independently, is alkyl, aryl, heteroaryl, alkoxyl, aryloxyl, heteroaryloxyl, alkoxylcarbonyl, aryloxylcarbonyl, or heteroaryloxylcarbonyl.

Abstract: A formulation and method for treating neoplasms such as cancer by administering a pharmaceutically effective amount or carboplatin by inhalation.

Abstract: Metal chelates of the amides of formula in which R has the formula Use in medical imaging.

Abstract: The invention provides methods for treating cancer and vanadium compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprision a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.

Abstract: Synthetic low molecular weight catalysts for the dismutation of superoxide are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics.

Abstract: The invention provides a method for enhancing the water solubility of cytotoxic trans-platinum complexes. The present invention also provides a method for killing tumor cells, and a method for the treatment of tumors by the administration of a cytotoxic platinum coordination complex of the general formula SP4-2-[PtX(L)(L′)(B)]+.

Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with: 1. aromatic carboxylic acids or their alkaline earth salts; 2. heterocyclic carboxylic acids or their alkaline earth salts; 3. amino acids or their alkaline earth salts; 4. amines; and 5. suitably substituted steroids. The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.

Abstract: Organometallic oxovanadium (IV) complexes having potent spermicidal activity, particularly those having at least one bidentate ligand. Preferred compounds are stable oxovanadium (IV) complexes having, as ancillary ligands linked via nitrogen or oxygen-metal bonds, bis and/or mono-1,10-phenanthroline; 2,2′-bipyridyl; or 2-hydroxyacetophenone.

Abstract: Organovanadium complexes, and more specifically hydroxyoxovanadium(V), &mgr;-oxo dimeric oxovanadium(V) and cis-dioxovanadium(V) complexes, are provided. The complexes may be formulated into a pharmaceutical composition. The complexes and/or compositions may be used in the treatment of a variety of disease states, including use as anti-proliferative and/or anti-metastatic agents and/or to treat drug resistant tumors and/or to methods of reducing the ability of tumors to metastasize and/or for the treatment of diabetes, arthritis, multiple sclerosis, diseases involving passageways of the body, and autoimmune diseases including but not limited to psoriasis and lupus.

Abstract: Magnesium (−)hydroxycitrate, preparation process, dietary and therapeutic uses particularly in the cardiovascular field, and compositions in particular pharmaceutical containing it.

Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide.

Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: wherein R, R′, R1, R′1, R2, R′2, R3, R′3, R4, R′4, R5, R′5, R6, R′6, R7, R′7, R8, R′8, R9, R′10, R10 and R′10, X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, myocardial infarction, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury.

Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.

Abstract: The present invention relates to tropane derivatives having particular use for the in vivo detection of dopamine transporters. These derivatives meet the formula in which R1 is I or Sn (R3)3, R2 is for example the methyl group, and X and Y are various substituents. The derivatives with X═CH3 and Y═H show strong specificity for the dopamine transporter compared with the serotonin transporter (74% inhibition when the transporter is previously saturated with GBR 12909).

Abstract: The invention relates to new porphyrin complex compounds, pharmaceutical agents that contain the latter, and the use of porphyrin complexes for the production of agents for photodynamic therapy and MRI diagnosis.

Abstract: Biologically active derivatives of the tropane ring system are provided which selectively bind either to the 5-HT or DA reuptake site, leading to compounds which have use for the treatment of clinical depression, attention deficit disorder, obesity and cocaine addiction.

Abstract: Compositions for preventing or treating memory loss in the brain, comprising an effective amount of a mixture of lecithin and vitamin B.sub.12.

Abstract: Heterocyclic derivatives of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Abstract: The present invention is directed to complexes represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, R'.sub.9, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.

Abstract: The present invention relates to an aqueous cleaning composition containing(a) 1 to 10 weight % of at least one surfactant selected from the group consisting of anionic surfactants and ethoxylated nonionic surfactants and mixtures thereof;(b) 0.2 to 10 weight % of a biostatic agent such as a C.sub.2 -C.sub.20 alkyl trimethyl ammonium halide, a C.sub.8 -C.sub.16 alkyl dimethyl benzyl ammonium halide, a polyhexamethylene biguanide hydrochloride, a 3-(trialkoxysilyl)propyl C.sub.14 -C.sub.20 alkyl dimethyl ammonium halide, ketoconazole, and zinc-bis(2-pyridinethiol 1-oxide); and(c) the balance being water; wherein said liquid cleaning composition does not contain a pigment, a chlorine containing bleach, peroxygen bleach, hydrogen peroxide, builder, water soluble or water dispersible organic binding agent, sequestering agent, acid dye, C.sub.8 -C.sub.18 fatty acid monoester of diglycerol, C.sub.8 -C.sub.

Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid, maltol and ethyl maltol.

Abstract: A method of treating diabetes in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutically acceptable VO.sup.+2 generating compound and a therapeutically effective amount of micronized glyburide.

Abstract: Inhibitor of the use of tetrahydrobiopterin as a cofactor for nitric oxide synthase, e.g., substituted 4-phenyl(hydropyridines) such as 1-methyl-4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine or, 4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine) or tetrahydropterin analog which does not replace tetrahydrobiopterin as a substrate for nitric oxide synthase such as (6R,S)-6,7-dimethyl-tetrahydropterin or (6R,S)-tetrahydrofolic acid or 2,4-diamino-, 2,6-diamino, or 4,6-diamino mono- or disubstituted pyrimidines or the corresponding pyrimidine-3-oxides such as 2,4-diamino-6-(diethylamino)pyrimidine, 2,4-diamino-6-piperidino-pyrimidine-3-oxide, 2,4-diamino-6-hydroxypyrimidine, 4,6-diamino-2-hydroxypyrimidine or 2,5-diamino-4,6-dihydroxypyrimidine is administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylaxis or treatment of cytokine- or endotoxin-induced hypotension (e.g., septic shock).

Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid, maltol and ethyl maltol.

Abstract: Polyazamacrocyclofluoromonoalkylphosphonic acid compounds are disclosed which form inert complexes with Gd, Mn, Fe or La ions. The complexes are useful as contrast agents for diagnostic purposes.